Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Leo Lee | Chief Executive Officer & Executive VP | -- | -- | -- |
| Ms. Yu-Ping Yang | Chief Financial Officer | -- | -- | -- |
| Mr. Shih-Shen Lee | Executive Vice President of Operations Business Unit | -- | -- | -- |
Medigen Vaccine Biologics Corporation
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Zhubei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.
Corporate Governance
Upcoming Events
March 6, 2025 at 10:59 AM UTC - March 10, 2025 at 12:00 PM UTC
Medigen Vaccine Biologics Corporation Earnings Date
Recent Events
Recent Events Information Not Available